11. Patients on proton pump inhibitors, potent CYP3A or P-glycoprotein substrates, inhibitors or inducers a minimum 7 day period washout required unless discontinuation or substitution is not in the best interests of the patient as determined by the investigator. In instances where use of these agents is felt to be required for optimal management, inclusion of such patients should be discussed with the PI and the rationale documented. These patients, if enrolled on study, may require dose modifications for both axitinib and bosutinib. The list of drugs that interact with cytochrome P450 enzymes can be found online at: http://medicine.iupui.edu/clinpharm/DDIs/ClinicalTable.aspx